We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Body Surface Area Can Determine Success of Liver Transplantation

By HospiMedica International staff writers
Posted on 02 May 2013
A new study determines the safe range of deceased liver transplantation graft-size mismatch using body surface area index (BSAi).

Researchers at the University of Miami (FL, USA) and the University of Tokyo (Japan) conducted a study involving 24,509 patients to develop a multivariate survival model that can be used to estimate the hazard risk of BSAi for three-year graft survival, using data derived from the US national registry database between 2005 and 2010. More...
BSAi was calculated by dividing the BSA of the donor with the BSA of recipient.

The results showed that small-for-size grafts (BSAi less than 0.78) had a significant impact on graft dysfunction, with progressive increase of hazard risk towards the lowest end and a higher incidence of primary graft nonfunction and vascular thrombosis. On the other hand, large-for-size grafts (BSAi greater than 1.24) had a significant impact on graft dysfunction with progressive increase of hazard risk towards the largest end. The study was published ahead of print on April 10, 2013, in Transplant International.

“In live donor liver transplantation, rigorous standardized criteria for matching of liver volume between donor and recipient have prevented graft loss due to size mismatch,” concluded lead author Kyota Fukazawa, MD, and colleagues of the division of solid organ transplantation. “Therefore, BSAi higher than 0.78 and lower than 1.24 appears to be a safe range to avoid adverse outcome associated with size mismatch in deceased liver transplantation.”

In physiology and medicine, BSA is the measured or calculated surface of a human body. For many clinical purposes, BSA is a better indicator of metabolic mass than body weight because it is less affected by abnormal adipose mass. Examples of uses of BSA include renal clearance, usually divided by the BSA to gain an appreciation of the true required glomerular filtration rate (GFR); chemotherapy, often dosed according to the patient's BSA; and glucocorticoid dosing, expressed in terms of BSA for calculating maintenance doses.

Related Links:

University of Miami
University of Tokyo



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Pediatric Mask
Respire SOFT
New
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.